26 results
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make
8-K
EX-1.1
VERV
Verve Therapeutics Inc
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
information (collectively with the pricing information set forth on Annex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated … the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares
DEFA14A
rub4orwic0kanvd6m
28 Apr 23
Additional proxy soliciting materials
7:49am
8-K
EX-99.1
pzjq35355krmix6wox7
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-1.1
6zt tysrij6k9nskwhna
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
DEFA14A
fdhu0q7hlto
29 Apr 22
Additional proxy soliciting materials
7:22am
DEF 14A
bshqb7 56i5l
29 Apr 22
Definitive proxy
7:01am
10-K
wa40o t5voo1
14 Mar 22
Annual report
7:04am
424B4
t4nd5qvkyf4dkh
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
EX-1.1
fusl1ftqh0jla
14 Jun 21
IPO registration (amended)
6:15am
S-1/A
q5nl2c
14 Jun 21
IPO registration (amended)
6:15am